Hidroxicarbamida Medac

Hydroxycarbamide (hydroxyurea) marketed as Hidroxicarbamida Medac is an oral antineoplastic and hematologic agent supplied in the European Union. It belongs to the antimetabolite class and functions as a ribonucleotide reductase inhibitor. The product is prescribed by healthcare professionals for specific blood‑related disorders and certain solid tumors. As a prescription‑only medication, it is intended for use under medical supervision and requires regular monitoring of blood counts.

Hidroxicarbamida Medac is indicated for several hematologic and oncologic conditions where reduction of abnormal cell proliferation is desired.

- Chronic myelogenous leukemia (CML) - Polycythemia vera - Essential thrombocythemia - Sickle cell disease (to reduce vaso‑occlusive crises) - Melanoma (as adjunct therapy) - Use in combination with other chemotherapeutic agents as directed by an oncologist

Adverse reactions to Hidroxicarbamida Medac vary in frequency and severity.

Common: - Nausea and vomiting - Loss of appetite - Mild skin rash - Mild leukopenia or anemia

Serious: - Severe bone marrow suppression (pancytopenia) - Hepatic toxicity - Renal impairment - Severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy with Hidroxicarbamida Medac, clinicians should evaluate several safety considerations.

- Obtain baseline complete blood count, liver and kidney function tests. - Assess pregnancy status; avoid use during pregnancy unless benefits outweigh risks. - Do not use in patients with pre‑existing severe bone marrow failure. - Monitor for signs of infection or fever during treatment. - Adjust dose in patients with renal impairment. - Advise patients to avoid live attenuated vaccines while on therapy.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or safety.

Avoid: - Concurrent use with protease inhibitors (e.g., ritonavir) that increase hydroxycarbamide levels. - Co‑administration with high‑dose vitamin C, which may enhance toxicity. - Combination with other myelosuppressive agents without dose adjustment.

Use with caution: - Allopurinol may increase risk of bone marrow suppression. - NSAIDs may increase risk of renal dysfunction. - Azathioprine may require close monitoring of blood counts.